COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?

被引:0
作者
T. Filardi
S. Morano
机构
[1] Policlinico Umberto I,Department of Experimental Medicine
[2] “Sapienza” University of Rome,undefined
来源
Journal of Endocrinological Investigation | 2020年 / 43卷
关键词
COVID-19; SARS-CoV-2; Diabetes; ACE2; DPP4; Diabetes therapy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1053 / 1060
页数:7
相关论文
共 491 条
[11]  
Sheng JF(2020)Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication Diabetes Care 101 236-548
[12]  
Cai HL(2020)Diabetes patients with COVID-19 need better blood glucose management in Wuhan China Metabolism 71 539-116
[13]  
Qiu YQ(2014)Resistant hypertension in patients with type 2 diabetes: clinical correlates and association with complications J Hypertens 93 543-627
[14]  
Li LJ(2018)The long-term impact of renin-angiotensin system (RAS) inhibition on cardiorenal outcomes (LIRICO): a randomized controlled trial J Am Soc Nephrol 436 112-136
[15]  
Zou X(2020)SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Cell 6 19840-404
[16]  
Chen K(2015)Novel RAAS agonists and antagonists: clinical applications and controversies Nat Rev Endocrinol 21 234-15676
[17]  
Zou J(2014)Deletion of angiotensin-converting enzyme 2 promotes the development of atherosclerosis and arterial neointima formation Cardiovasc Res 225 618-647
[18]  
Han P(2020)Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers Hypertension 481 131-374
[19]  
Hao J(2019)Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure Pharmacol Rev 43 395-953
[20]  
Han Z(2008)The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice Exp Physiol 8 15670-725